antibody-dependent cell-mediated cytotoxicity

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to antibody-dependent cell-mediated cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)


1. the degree to which an agent has specific destructive action on certain cells.
2. the possession of such destructive action, particularly in reference to lysis of cells by immune phenomena and to antineoplastic agents that selectively kill dividing cells. adj., adj cytotox´ic.
antibody-dependent cell-mediated cytotoxicity (ADCC) (antibody-dependent cellular cytotoxicity) lysis of target cells coated with antibody by effector cells with cytolytic activity and specific immunoglobulin receptors called Fc receptors, including K cells, macrophages, and granulocytes. Lysis of the target cell is extracellular, requires direct cell-to-cell contact, and does not involve complement.
cell-mediated cytotoxicity destruction of a target cell by specific lymphocytes, such as cytotoxic T lymphocytes or NK cells; it may be antibody-dependent (see antibody-dependent cell-mediated c.) or independent, as in certain cell-mediated hypersensitivity reactions.

an·ti·bo·dy-de·pen·dent cell-·me·di·at·ed cy·to·tox·i·ci·ty (ADCC),

a form of cell-mediated cytotoxicity mediated by natural killer cells with membrane bound Fc receptors. NK cells bind to antibody-coated microbes and the target cell may be killed through various modalities, for example, perforin, reactive oxygen intermediates, cytokines.

antibody-dependent cell-mediated cytotoxicity

The killing of a target cell, which has been coated with an antibody, by a MACROPHAGE, neutrophil or natural killer cell that carries the surface receptor that binds to the particular antibody.
References in periodicals archive ?
Using Xencor's XmAb Fc enhancement technology, MOR208 has been engineered to possess enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which is said to improve a key mechanism for tumor cell killing and offering potential for enhanced efficacy when compared to traditional antibodies for the treatment of cancer.
Galiximab's potential mechanisms of action include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and possible immunomodulatory effects on host effector cells affecting the tumor microenvironment.
In previously conducted pre-clinical studies, XmAb5574 demonstrated that it is highly cytotoxic against lymphoma and leukemia cell lines and that its antibody-dependent cell-mediated cytotoxicity (ADCC) and efficacy is superior to rituximab, the current standard of care for the treatment of non-Hodgkin lymphoma (NHL).

Full browser ?